Clinical Pharmacokinetics and Pharmacodynamics of Isepamicin

[1]  M. Tod,et al.  Isepamicin in intensive care unit patients with nosocomial pneumonia: population pharmacokinetic-pharmacodynamic study. , 1999, The Journal of antimicrobial chemotherapy.

[2]  F. Torricelli,et al.  Inherited susceptibility to aminoglycoside ototoxicity: genetic heterogeneity and clinical implications. , 1999, American journal of otolaryngology.

[3]  G. Drusano,et al.  Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria , 1999, Antimicrobial Agents and Chemotherapy.

[4]  M. Barclay,et al.  Once Daily Aminoglycoside Therapy , 1999, Clinical pharmacokinetics.

[5]  J. Schacht,et al.  Stimulation of free radical formation by aminoglycoside antibiotics 1 The data in this paper have been presented, in part, at the meeting of the Association for Research in Otolaryngology, February 1996. 1 , 1999, Hearing Research.

[6]  J. Aran,et al.  Attenuation of aminoglycoside-induced cochlear damage with the metabolic antioxidant α-lipoic acid , 1999, Hearing Research.

[7]  J. Schacht,et al.  Iron chelators protect from aminoglycoside-induced cochleo- and vestibulo-toxicity. , 1998, Free radical biology & medicine.

[8]  D. Nicolau,et al.  The pharmacodynamics of aminoglycosides. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  S. Komune,et al.  Isepamicin Sulfate-Induced Sensorineural Hearing Loss in Patients with the 1555 A→G Mitochondrial Mutation , 1998, ORL.

[10]  B. Uzzan,et al.  Population Pharmacokinetic Study of Amikacin Administered Once or Twice Daily to Febrile, Severely Neutropenic Adults , 1998, Antimicrobial Agents and Chemotherapy.

[11]  J. Izquierdo,et al.  Postantibiotic and Sub-MIC Effects of Azithromycin and Isepamicin against Staphylococcus aureus and Escherichia coli , 1998, Antimicrobial Agents and Chemotherapy.

[12]  D. Izard,et al.  [Sensitivity of Pseudomonas aeruginosa to amikacin and to isepamicin in surgery and in intensive care]. , 1997, Pathologie-biologie.

[13]  K. Shaw,et al.  Cloning and characterization of an aminoglycoside 6'-N-acetyltransferase gene from Citrobacter freundii which confers an altered resistance profile , 1997, Antimicrobial agents and chemotherapy.

[14]  A. Nomeir,et al.  Pharmacokinetics of isepamicin following a single administration by intravenous infusion or intramuscular injections , 1997, Antimicrobial agents and chemotherapy.

[15]  P. Speelman,et al.  Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients , 1997, Clinical pharmacology and therapeutics.

[16]  J. Rotschafer,et al.  Editorial Response: Single Daily Dosing of Aminoglycosides—A Concept Whose Time Has Not Yet Come , 1997 .

[17]  D. Gilbert.  Meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  R. Hatala,et al.  Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  A. Bayer,et al.  Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model , 1997, Antimicrobial agents and chemotherapy.

[20]  M. Cayen,et al.  Pharmacokinetics of intramuscularly administered isepamicin in man. , 1997, Chemotherapy.

[21]  Claude Carbón,et al.  Resistance to amikacin and isepamicin in rabbits with experimental endocarditis of an aac(6')-Ib-bearing strain of Klebsiella pneumoniae susceptible in vitro , 1996, Antimicrobial agents and chemotherapy.

[22]  P. Speelman,et al.  Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy , 1996, Antimicrobial agents and chemotherapy.

[23]  M. Tod,et al.  Population pharmacokinetic study of isepamicin with intensive care unit patients , 1996, Antimicrobial agents and chemotherapy.

[24]  P. Glue,et al.  Effect of age on the pharmacokinetics of isepamicin, a new once daily aminoglycoside , 1996 .

[25]  R. Colucci,et al.  The effect of renal function on felbamate clearance , 1996 .

[26]  M. Cayen,et al.  Pharmacokinetics of intravenously administered isepamicin in men , 1995, Antimicrobial agents and chemotherapy.

[27]  Eric M. Priuska,et al.  Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex. , 1995, Biochemical pharmacology.

[28]  A. Nomeir,et al.  Pharmacokinetics and metabolism of 14C-isepamicin in humans following intravenous administration , 1995, Antimicrobial agents and chemotherapy.

[29]  D. Blum.  An overview of the safety of isepamicin in adults. , 1995, Journal of chemotherapy.

[30]  E. Ongini,et al.  Auditory impairment in guinea pigs treated with isepamicin. , 1995, Journal of chemotherapy.

[31]  W. H. Barr,et al.  Pharmacokinetics of isepamicin. , 1995, Journal of chemotherapy.

[32]  G. Beaucaire.  Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia. , 1995, Journal of chemotherapy.

[33]  V. Leblond,et al.  Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients. , 1995, Journal of chemotherapy.

[34]  R. Jones.  Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity. , 1995, Journal of chemotherapy.

[35]  K. Shaw,et al.  The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin--a new broad-spectrum aminoglycoside. The Aminoglycoside Resistance Study Groups. , 1995, Journal of chemotherapy.

[36]  W. Craig,et al.  Once-daily versus multiple-daily dosing of aminoglycosides. , 1995, Journal of chemotherapy.

[37]  C H Nightingale,et al.  Experience with a once-daily aminoglycoside program administered to 2,184 adult patients , 1995, Antimicrobial agents and chemotherapy.

[38]  R. Brasseur,et al.  Molecular parameters involved in aminoglycoside nephrotoxicity. , 1995, Journal of toxicology and environmental health.

[39]  Jerome J. Schentag,et al.  The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to Outcome , 1995, Clinical pharmacokinetics.

[40]  P. Kosmidis,et al.  A comparative study with two administration schedules of leucovorin and 5-fluorouracil in advanced colorectal cancer. , 1995, Journal of chemotherapy.

[41]  H. Georges,et al.  Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily , 1995, Antimicrobial agents and chemotherapy.

[42]  K. Shaw,et al.  The most frequently occurring aminoglycoside resistance mechanisms--combined results of surveys in eight regions of the world. The Aminoglycoside Resistance Study Groups. , 1995, Journal of chemotherapy.

[43]  G. Cortopassi,et al.  Proposed molecular and cellular mechanism for aminoglycoside ototoxicity , 1994, Antimicrobial Agents and Chemotherapy.

[44]  J. Schacht,et al.  Sulfhydryl compounds and antioxidants inhibit cytotoxicity to outer hair cells of a gentamicin metabolite in vitro , 1994, Hearing Research.

[45]  R. Farinotti,et al.  Activity of isepamicin and selection of permeability mutants to beta-lactams during aminoglycoside therapy of experimental endocarditis due to Klebsiella pneumoniae CF104 producing an aminoglycoside acetyltransferase 6' modifying enzyme and a TEM-3 beta-lactamase. , 1994, The Journal of infectious diseases.

[46]  T. Uematsu.  Population pharmacokinetic analysis of new aminoglycosides, astromicin and isepamicin, and evaluation of Bayesian prediction method for approximation of individual clearance of drug. , 1993, International journal of clinical pharmacology, therapy, and toxicology.

[47]  J. Flandrois,et al.  A statistical evaluation of the bactericidal effects of ceftibuten in combination with aminoglycosides and ciprofloxacin. , 1993, The Journal of antimicrobial chemotherapy.

[48]  Yasufumi Sato,et al.  Effect of Hemodialysis on Serum Concentration of Isepamicin in a Patient with Endstage Renal Failure , 1993, The Annals of pharmacotherapy.

[49]  M. Paesmans,et al.  Efficacy and Toxicity of Single Daily Doses of Amikacin and Ceftriaxone versus Multiple Daily Doses of Amikacin and Ceftazidime for Infection in Patients with Cancer and Granulocytopenia , 1993, Annals of Internal Medicine.

[50]  F. Luft,et al.  Calcium antagonists and renal protection. , 1993, Renal failure.

[51]  R. Bryant,et al.  Beta-lactam enhancement of aminoglycoside activity under conditions of reduced pH and oxygen tension that may exist in infected tissues. , 1992, The Journal of infectious diseases.

[52]  J. McCormack,et al.  A critical reevaluation of the "therapeutic range" of aminoglycosides. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  L. Kaufman,et al.  Effect of isepamicin dosing scheme on concentration in cochlear tissue , 1991, Antimicrobial Agents and Chemotherapy.

[54]  C. Halstenson,et al.  Isepamicin disposition in subjects with various degrees of renal function , 1991, Antimicrobial Agents and Chemotherapy.

[55]  R. Jones,et al.  Antimicrobial activity of isepamicin (SCH21420, 1-N-HAPA gentamicin B) combinations with cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem, mezlocillin and piperacillin tested against gentamicin-resistant and susceptible gram-negative bacilli and enterococci. , 1991, Journal of chemotherapy.

[56]  W. Craig,et al.  Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli. , 1991, The Journal of antimicrobial chemotherapy.

[57]  G. Jackson,et al.  First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use , 1991, Antimicrobial Agents and Chemotherapy.

[58]  W. Craig,et al.  Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. , 1991, The Journal of antimicrobial chemotherapy.

[59]  S. Norrby.  Treatment failures with broad-spectrum antibiotics. , 1991, Scandinavian journal of infectious diseases. Supplementum.

[60]  E. Ongini,et al.  Simple measurement of isepamicin, a new aminoglycoside antibiotic, in guinea pig and human plasma, using high-performance liquid chromatography with ultraviolet detection. , 1991, Therapeutic drug monitoring.

[61]  G. Matzke,et al.  Effect of concomitant administration of piperacillin on the dispositions of netilmicin and tobramycin in patients with end-stage renal disease , 1990, Antimicrobial Agents and Chemotherapy.

[62]  W. Awni,et al.  High-performance liquid chromatographic determination of isepamicin in plasma, urine and dialysate. , 1990, Journal of chromatography.

[63]  M. D. de Broe,et al.  Once‐daily dosing decreases renal accumulation of gentamicin and netilmicin , 1989, Clinical pharmacology and therapeutics.

[64]  M. Nakashima,et al.  Evaluation of a Fluorescence Polarization Immunoassay Procedure for Quantitation of Isepamicin, a New Aminoglycoside Antibiotic , 1988, Therapeutic drug monitoring.

[65]  J. Turnidge,et al.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. , 1988, The Journal of infectious diseases.

[66]  Sally E. Williams,et al.  Three molecular steps of aminoglycoside ototoxicity demonstrated in outer hair cells , 1987, Hearing Research.

[67]  J. Blaser,et al.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance , 1987, Antimicrobial Agents and Chemotherapy.

[68]  Jerome J. Schentag,et al.  Single-dose accumulation pharmacokinetics of tobramycin and netilmicin in normal volunteers , 1987, Antimicrobial Agents and Chemotherapy.

[69]  R. Moore,et al.  Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. , 1987, The Journal of infectious diseases.

[70]  J. E. Murphy,et al.  Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. , 1986, Clinical pharmacy.

[71]  M. D. de Broe,et al.  In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. , 1986, The Journal of pharmacology and experimental therapeutics.

[72]  J. Sculier,et al.  Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. , 1984, The American journal of medicine.

[73]  J. Longstreth,et al.  Netilmicin and gentamicin multidose kinetics in normal subjects , 1983, Clinical pharmacology and therapeutics.

[74]  A. Astier,et al.  [Pharmacokinetics of gentamicin in the decompensed alcoholic cirrhotic patient. Therapeutic consequences]. , 1983, Pathologie-biologie.

[75]  Everett Ed,et al.  Endobronchial pH. Relevance of aminoglycoside activity in gram-negative bacillary pneumonia. , 1983 .

[76]  R. Jones,et al.  Comparison of in vitro activity of Sch 21420, a gentamicin B derivative, with those of amikacin, gentamicin, netilmicin, sisomicin, and tobramycin , 1980, Antimicrobial Agents and Chemotherapy.

[77]  A. Kucers.  Use of Antibiotics , 1979 .

[78]  P. Lacy,et al.  Effect of ethanol and n-butanol on alloxan inhibition of glucose-induced insulin release in isolated pancreatic islets. , 1978, Biochemical pharmacology.